miR-143-5p as a Prognostic Biomarker in Colorectal Cancer: Inhibition of Tumor Progression Through Targeting MYCBP

Background/Aims: miR-143-5p functions as a tumor-suppressive microRNA across various cancer types. The current study investigated the expression, prognostic value, and role of miR-143-5p in colorectal cancer (CRC).

Materials and Methods: The expression of miR-143-5p was measured by quantitative reverse transcription polymerase chain reaction. Associations between miR-143-5p expression and clinicopathological characteristics of patients with CRC were statistically analyzed. A series of in vitro cell-based assays were performed to investigate the underlying regulatory mechanisms.

Results: miR-143-5p was downregulated in CRC and may serve as a promising independent prognostic biomarker. Reduced miR- 143-5p expression was associated with adverse clinicopathological characteristics and decreased 5-year overall survival. MYCBP was identified as a direct target of miR-143-5p. Overexpression of miR-143-5p suppressed the malignant behaviors of CRC cells, which were partially restored by enforced MYCBP expression.

Conclusion: miR-143-5p is downregulated in CRC and may function as a potential independent prognostic biomarker. Moreover, miR- 143-5p may play a tumor-suppressive role in CRC by specifically targeting MYCBP.

Cite this article as: Mu C, Zhang H. MiR-143-5p as a prognostic biomarker in colorectal cancer: Inhibition of tumor progression through targeting MYCBP. Turk J Gastroenterol. Published online July 21, 2026. doi: 10.5152/tjg.2026.26198.